EPAT PLAYS A KEY ROLE IN WORKING TOWARDS DISCOVERING INNOVATIVE BREAKTHROUGHS BY COMBINING OUR BIOLOGICS-BASED PRECISION MEDICINES WITH EISAI’S VAST KNOWLEDGE OF CHEMICALS AND GENETICS.
That’s the goal at Epochal Precision Anti-Cancer Therapeutics (EPAT), our Biologics Discovery Center located in Exton, Pennsylvania. EPAT is developing precision oncology therapies by combining biologics expertise, Eisai’s unique Antibody-Drug Conjugate (ADC) technology, proprietary payloads and bispecific antibodies.
EPAT is focused on developing breakthrough therapies for patients living with a variety of cancers, especially in these key areas of unmet medical need:
ADCs are next-generation biopharmaceutical drugs consisting of targeted molecular antibodies linked to anti-cancer drugs. An ADC is designed to target and bind to specific cancer cells, then release the anti-cancer “warhead” into the cancer cells to cause cell death (apoptosis), followed by “bystander effects” on the surrounding cells. The hope behind this “smart” approach is both to maximize bystander effects on the tumor microenvironment and to minimize bystander effects on healthy cells , leading to fewer unintended side effects. Our first ADC drug, MORAb-202, is now being developed in clinical phase 1 study in Japan .
Eribulin* ADC Payload
*Any ADC employing eribulin as a payload is investigational and has not been approved by regulatory authorities. For more information on HALAVEN® (eribulin mesylate), please see www.halaven.com or contact Eisai’s Medical Information toll-free number: 1-888-274-2378.
Get an in-depth look at EPAT’s proprietary technologies, including: